Arcus Biosciences, Inc. Increase (Decrease) in Other Current Liabilities
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Other Current Liabilities of $1.87 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2022-02-23
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for the quarter ending 2019-12-31 was $15.00K, a 50.00% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for the quarter ending 2019-09-30 was $13.00K, a 0.00% change year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for the quarter ending 2019-06-30 was $15.00K, a 36.36% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for fiscal 2019 was $57.00K, a 32.56% increase from fiscal 2018.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for fiscal 2018 was $43.00K.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for fiscal 2017 was -$136.00K, a 121.02% decline from fiscal 2016.
- Arcus Biosciences, Inc. increase (decrease) in other current liabilities for fiscal 2016 was $647.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2020-09-30 | $1.87M 10-Q · filed 2021-11-08 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 | $15.00K derived: sum of 2 quarters · filed 2022-02-23 | $28.00K derived: sum of 3 quarters · filed 2022-02-23 | $43.00K derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $28.00K derived: sum of 2 quarters · filed 2022-02-23 | $43.00K derived: sum of 3 quarters · filed 2022-02-23 | $57.00K 10-K · filed 2022-02-23 |
| 2019-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $28.00K derived: sum of 2 quarters · filed 2020-11-05 | $42.00K 10-Q · filed 2020-11-05 | $52.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $29.00K 10-Q · filed 2020-08-06 | $39.00K derived: sum of 3 quarters · filed 2021-02-25 | $52.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $14.00K 10-Q · filed 2020-05-05 | $24.00K derived: sum of 2 quarters · filed 2021-02-25 | $37.00K derived: sum of 3 quarters · filed 2021-02-25 | $48.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $23.00K derived: sum of 2 quarters · filed 2021-02-25 | $34.00K derived: sum of 3 quarters · filed 2021-02-25 | $43.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $24.00K derived: sum of 2 quarters · filed 2019-11-05 | $33.00K 10-Q · filed 2019-11-05 | -$131.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $20.00K 10-Q · filed 2019-08-06 | -$144.00K derived: sum of 3 quarters · filed 2019-08-06 | -$136.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $9.00K 10-Q · filed 2019-05-02 | -$155.00K derived: sum of 2 quarters · filed 2019-05-02 | -$147.00K derived: sum of 3 quarters · filed 2019-05-02 | -$137.00K derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | -$164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$156.00K derived: sum of 2 quarters · filed 2019-03-05 | -$146.00K derived: sum of 3 quarters · filed 2019-03-05 | -$136.00K 10-K · filed 2019-03-05 |
| 2017-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $18.00K derived: sum of 2 quarters · filed 2018-11-08 | $28.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $20.00K 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $10.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $647.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |